Sunesis Pharmaceuticals Inc (SNSS)
Sunesis Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of new therapeutics for the treatment of cancer. Co.'s primary activities are conducting research and development internally and through corporate collaborators, in-licensing and out-licensing pharmaceutical compounds and technology, conducting clinical trials and raising capital. Co.'s primary program is vecabrutinib, a non-covalent inhibitor of Bruton's Tyrosine Kinase. Co. is also developing SNS-510, a phosphoinositide-dependent kinase-1 inhibitor licensed from Millennium Pharmaceuticals, Inc., a wholly-owned subsidiary of Takeda Pharmaceutical Company Limited.